nach oben

Reactions Weekly

Erschienen in:

01.10.2019 | Case report

Ocrelizumab

Infusion-related reaction: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In an open-label, longitudinal cohort study of 281 patients (aged 23−80 years) with multiple sclerosis (MS), who received ocrelizumab between 4 May 2017 and 10 May 2018, a patient [age and sex not stated] was described, who developed infusion-related reaction during treatment with ocrelizumab infusion [dosage not stated] for MS [time to reaction onset not stated]. Subsequently, ocrelizumab was stopped [outcome not stated]. …

Belcher S, et al. Reduction of infusion related reactions during ocrelizumab infusions in a comprehensive multiple sclerosis Care Center. Multiple Sclerosis Journal 24 (Suppl. 2): 717-718 abstr. P1257, 2018. Available from: URL: http://doi.org/10.1177/1352458518798591 [abstract] - USA

Titel: Ocrelizumab
Infusion-related reaction: case report
Publikationsdatum: 01.10.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-70501-2

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Ocrelizumab

Infusion-related reaction: case report

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Cisplatin

Prednisone/teriflunomide

Cotrimoxazole

Yellow fever vaccine

Colecalciferol overdose/misuse

Epinephrine/norepinephrine/plasma